Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?

Purpose This multicenter retrospective study assessed the real-world effectiveness and safety of upadacitinib in adults with moderate-to-severe atopic dermatitis across eight centers in central Italy.Materials and methods A total of 150 patients received upadacitinib 15 mg or 30 mg daily as monother...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Edoardo Mortato, Niccolò Gori, Giacomo Caldarola, Marina Talamonti, Claudia Paganini, Luisa Boeti, Filomena Russo, Teresa Grieco, Ersilia Tolino, Gaia Moretta, Flavia Pigliacelli, Rosa Coppola, Domenico Giordano, Camilla Chello, Concetta Potenza, Maria Concetta Fargnoli, Vincenzo Panasiti, Barbara Cocuroccia, Ketty Peris, Marco Galluzzo
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Taylor & Francis Group 2025-12-01
Serie:	Journal of Dermatological Treatment
Ämnen:	Upadacitinib atopic dermatitis head and neck dermatitis JAK inhibitors
Länkar:	https://www.tandfonline.com/doi/10.1080/09546634.2025.2509541
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!